Skip to main content

Age-Related Macular Degeneration and Its Management

  • Chapter
Geriatric Ophthalmology
  • 730 Accesses

Abstract

A 75-year-old woman notes increasing difficulty with reading and walking down steps in dim light over the past 6 months. During her last comprehensive eye examination 1 year ago, she recalls that she had been diagnosed with early cataracts and also was told she had the beginning signs of macular degeneration. While she was somewhat anxious with this latter diagnosis, her doctor told her to consider taking a dietary supplement. She bought a multivitamin with lutein over the counter as she heard from a friend that people with macular degeneration should take this supplement. She believed that her progressive difficulty with vision was either because her glasses needed changing or her cataracts were worsening, or she was just losing vision with age.

Adapted in part from Clinical Advances in Age-Related Macular Degeneration, Johns Hopkins University School of Medicine Continuing Medical Education Enduring Material, 2007–2008.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900–1901.

    Article  PubMed  CAS  Google Scholar 

  2. The Age-Related Eye Disease Study Research Group. Potential public health impact of AREDS results: AREDS Report No. 11. Arch Ophthalmol. 2003;121:1621–1624.

    Google Scholar 

  3. Rosenfeld PJ, Brown DM, Heier JS, et al. for the MARINA study group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.

    Article  PubMed  CAS  Google Scholar 

  4. Brown DM, Kaiser PK, Michels M, et al. Schneider S for the ANCHOR study group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med. 2006;355:1432–1444.

    Article  CAS  Google Scholar 

  5. The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–1436.

    Google Scholar 

  6. Charkoudian LD, Gower EW, Solomon SD, Schachat AP, Bressler NB, Bressler SB. Vitamin usage patterns in the prevention of advanced age-related macular degeneration. Ophthalmology. 2008;115(6):1032–1038.e4.

    Article  PubMed  Google Scholar 

  7. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS) AREDS Report No. 19. Ophthalmology. 2005;112:533–539.

    Article  Google Scholar 

  8. The Age-Related Eye Disease Study Research Group. A simplified severity scale for age-related macular degeneration. AREDS Report No. 18. Arch Ophthalmol. 2005;123:1570–1574.

    Article  Google Scholar 

  9. American Academy of Ophthalmology. Age-Related Macular Degeneration: Medical Therapy and Surgery. Preferred Practice Pattern. San Francisco; American Academy of Ophthalmology, 2006. Available at aao.org/ppp.

    Google Scholar 

  10. Jampol LM. Bevacizumab vs ranibizumab treatment for age-related macular degeneration: A head-to-head comparison is needed. Arch Ophthalmol. 2007;125:557–558.

    Article  Google Scholar 

  11. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward HM, Klesert TR. For the MARINA study group: Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460–1469.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bressler, N.M. (2009). Age-Related Macular Degeneration and Its Management. In: Lee, A.G., Beaver, H. (eds) Geriatric Ophthalmology. Springer, New York, NY. https://doi.org/10.1007/b137372_6

Download citation

  • DOI: https://doi.org/10.1007/b137372_6

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-0009-8

  • Online ISBN: 978-1-4419-0014-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics